The Recall Desk
Agency classClass IOur severity:SevereFDA (Drugs)·D-0183-2023·Announced 2023-02-01

Advil Liqui Gels Minis Recalled for Illegible Label Due to Adhesive Migration

Glaxosmithkline Consumer Healthcare is recalling Advil Liqui Gels (minis) 200mg capsules nationwide due to illegible labeling caused by adhesive migration. Consumers should discard affected product or return it to the retailer.

The agency’s classification

FDA (Drugs): Class I

Class I is a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.

This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work

What this means for you

Our assessment, not the agency’s: severity 4/5 (Severe).

The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: This is an FDA Class I recall, which mandates a minimum severity score of 4 per the rubric. No deaths or serious injuries have been reported, so the score does not escalate to 5.

Plain-English summary

Glaxosmithkline Consumer Healthcare Holdings (DBA Haleon) is recalling Advil Liqui Gels (minis), which are ibuprofen 200mg liquid-filled capsules marketed as a pain reliever and fever reducer. The recall affects 209,292 capsules distributed nationwide in the United States.

The recall is due to a labeling defect in which adhesive used on the label migrated onto a portion of the label, causing it to tear when peeled back. This results in an illegible label that may not clearly display dosing instructions or other important product information.

The recall applies to the following lot codes: R93517, R94072, and R94073 (expiration date 02/29/2024), and lot code T00655 (expiration date 03/31/2025). Consumers who have purchased affected product should stop using it immediately.

Consumers should discard the affected product or return it to the retailer where it was purchased. For additional information, consumers can contact the FDA or the manufacturer.

The recalled product

Product
Advil Liqui Gels (minis), Solubilized ibuprofen capsules, 200mg, Pain Reliever Fever Reducer (NSAID), 200 liquid filled capsules, Pfizer, Madison, NJ 07940, UPC 3 0573 1769 13 5
Manufacturer
Glaxosmithkline Consumer Healthcare Holdings DBA Haleon
Category
Drug — OTC Pain Reliever
Hazard
Affected units
209,292

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (6)

  • Lot: R93517
  • R94072
  • R94073
  • Exp 02/29/2024
  • T00655
  • Exp 03/31/2025

Distribution

Distributed nationwide across the United States.

Part of a larger recall action

This product is one of 3 recalled by Glaxosmithkline Consumer Healthcare Holdings DBA Haleon under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.

See all 3 products in this recall →

Related recalls

Same manufacturer · Glaxosmithkline Consumer Healthcare Holdings DBA Haleon

See all →

Same hazard · mis labeling

See all →

Similar recalls